Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells by Xavier, Cristina P. R. et al.
1Title 
Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and 
inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer 
cells
Cristina P.R. Xavier1,2, Cristovao F. Lima1,3, Ana Preto1,2,4, Raquel Seruca4, Manuel 
Fernandes-Ferreira1,3 and Cristina Pereira-Wilson1,2, *
1Department of Biology, University of Minho, 4710-057 Braga, Portugal
2CBMA – Molecular and Environmental Biology Centre
3CITAB – Centro de Investigação e de Tecnologias Agro-Ambientais e Biológicas
4Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 
4200-465 Porto, Portugal 
* Corresponding author: Tel.: +351 253604318; fax: +351 253678980 (C. Pereira-
Wilson).
E-mail address: cpereira@bio.uminho.pt (C. Pereira-Wilson).
* Manuscript with track changes 2
2Abstract1
KRAS and BRAF mutations are frequent in colorectal carcinoma (CRC) and 2
have the potential to activate proliferation and survival through MAPK/ERK and/or3
PI3K signalling pathways. Because diet is one of the most important determinants of 4
CRC incidence and progression, we studied the effects of the dietary phytochemicals 5
quercetin (Q), luteolin (L) and ursolic acid (UA) on cell proliferation and apoptosis in 6
two human CRC derived cell lines, HCT15 and CO115, harboring KRAS and BRAF7
activating mutations, respectively. In KRAS mutated HCT15 cells, Q and L 8
significantly decreased ERK phosphorylation, whereas in BRAF mutated CO115 cells 9
the three compounds decreased Akt phosphorylation but had no effect on phospho-10
ERK. Our findings show that these natural compounds have antiproliferative and 11
proapoptotic effects and simultaneously seem to act on KRAS and PI3K but not on 12
BRAF. These results shed light on the molecular mechanisms of action of Q, L and UA 13
and emphasize the potential of dietary choices for the control of CRC progression. 14
15
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3Introduction18
Colorectal carcinoma (CRC) is the third most common cancer worldwide. In 19
particular sporadic CRC corresponding to 70-80% of total cases [1] is influenced by 20
environmental factors, many of which diet related [2]. The mitogen-activated protein 21
kinase/extracellular signal-regulated kinase (MAPK/ERK) and the phosphatidylinositol 22
3-kinase (PI3K)/Akt are signalling pathways that have been implicated in oncogenic 23
transformation in CRC. They confer a proliferative phenotype and resistance to therapy24
which is reflected in low patient survival [3-7]. Components of MAPK/ERK and 25
PI3K/Akt pathways constitute, therefore, molecular targets for anticancer strategies [8-26
10]. Mutations of either KRAS (32%) or BRAF (14%) genes occur alternatively [11] in 27
CRC, causing activation of either MAPK/ERK and PI3K pathways or MAPK/ERK 28
pathway, respectively. Activation of MAPK/ERK pathway regulates the expression of a 29
large number of proteins involved in the control of cell proliferation, differentiation and 30
apoptosis [4, 12]. Activation of PI3K gene and inactivation of PTEN, common in CRC,31
result in overexpression of downstream targets, including Akt and PKC, which promote 32
cell growth and rescue from apoptosis [13-17]. 33
Epidemiological studies show that cancer incidence is inversely correlated with 34
the consumption of diets rich in fruits and vegetables [18]. Natural compounds present 35
in the diet, such as resveratrol and curcumin have been shown to be protective against 36
cancer, contributing to decrease cancer risk and progression rate through their effects on 37
signalling pathways related to proliferation and apoptosis [18, 19]. Studies in cell lines 38
and animal models have shown that flavonoids inhibit cell proliferation and induce 39
apoptosis in many types of cancer cells through different signalling pathways, which 40
corroborate the suggestion that dietary choices may limit cancer progression [20-22]. 41
Quercetin (Q) and luteolin (L) (Figure 1) are two flavonoids found in fruits, vegetables 42
4and aromatic plants with high antioxidant activity [23] to which anticancer properties in 43
CRC are attributed [24-27]. In addition, a recent study showed that quercetin reduces 44
the formation of aberrant crypt foci in a rat colon cancer induction model, suggesting 45
the importance of this compound also in the prevention of colon cancer by decreasing 46
cancer initiating events [28]. Although structurally related, the absence of the hydroxyl 47
group at position 3 of L renders it more lipophilic than Q which may confer better 48
access to intracellular targets. In agreement with this, we have previously shown that L 49
is a more potent intracellular antioxidant than Q, and that this was related with its higher 50
lipophilicity [23]. Ursolic acid (UA; Figure 1), a natural pentacyclic triperpenoid 51
carboxylic acid, present ubiquitously in plant foods and also a major constituent in some 52
medicinal plants possesses a wide range of biological activities, such as 53
hepatoprotective and anti-inflammatory properties combined with low toxicity [29-31]. 54
However, contrarily to Q and L, UA is not an antioxidant at relevant cellular levels [32].55
Antitumor properties have also been attributed to UA and in colon cancer cells UA has 56
been shown to induce apoptosis and inhibit proliferation [33-35]. Although potential 57
effects on proliferation have been described for these compounds their effects on 58
MAPK/ERK and PI3K pathways have not been established.59
In spite of the general benefit of plant rich diets, variation in cancer incidence 60
among individuals with similar dietary habits suggests interactions of food constituents 61
with genetic factors [2, 18]. In the present study we report on the effects of Q, L and UA 62
on two human derived cell lines which harbor different oncogene activating mutations, 63
representative of a large number of CRC: HCT15 has a KRAS (G13D) mutation [36]64
whereas CO115 has a BRAF (V599E) mutation [37]. These mutations impact on 65
MAPK/ERK and PI3K pathways. The relevance of effects on both these pathways for 66
successful cancer treatment has recently been emphasized [38]. CRC remains a human 67
5malignant tumor often resistant to available treatment and knowledge of anticancer 68
properties of dietary constituents may guide dietary choices for cancer patients with 69
particular genetic backgrounds and possibly also suggest their use in combination with 70
conventional therapy in order to enhance therapeutic effects [39, 40]. 71
72
Material and methods73
74
Reagents and antibodies75
Quercetin (Q), ursolic acid (UA), wortmannin (W) and 3-(4,5-Dimethylthiazol-76
2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. 77
Louis, MO, USA). Luteolin (L) was from Extrasynthese (Genay, France) and PD-98059 78
(PD) from Calbiochem (San Diego, CA). All other reagents and chemicals used were of 79
analytical grade. Stock solutions of Q, L and UA were made in dimethyl sulfoxide 80
(DMSO) and aliquots kept at -20ºC.81
Primary antibodies were purchased from the following sources: Cell Signaling 82
(Danvers, MA, USA) the anti-p44/42 MAPK (ERK1/2) total, anti-phospho-Akt 83
(Ser473), anti-Akt total, anti-phospho-PTEN (Ser380/Thr382/383) and anti-PTEN total; 84
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) the anti-phospho-ERK1/2, Raf-85
B and K-Ras; and Sigma-Aldrich the anti-β-actin. Secondary antibodies HRP donkey 86
anti-rabbit and sheep anti-mouse were purchased from GE Healthcare (Bucks, UK).87
88
Cell culture 89
HCT15 and CO115 human colon carcinoma-derived cell lines were maintained 90
at 37ºC in a humidified 5% CO2 atmosphere in RPMI-1640 medium (Sigma-Aldrich) 91
supplemented with 10mM HEPES, 0.1mM pyruvate, 1% antibiotic/antimycotic solution 92
6(Sigma-Aldrich) and 10% fetal bovine serum (FBS; EU standard, Lonza, Verviers, 93
Belgium). Cells were seeded onto six (2ml) and twelve (1ml) well plates at a density of 94
0.75105 (HCT15) and 1.0105 (CO115) cells/ml. Incubations with different 95
concentrations of test compounds were made in serum free medium for 48h for MTT 96
test, BrdU incorporation and TUNEL assay, and for 24h (Akt, ERK and PTEN) or 6h 97
(BRAF and KRAS) for western blot analysis.98
99
Assessment of cell toxicity/proliferation by MTT reduction test100
A MTT reduction assay of the tested compounds was performed in order to 101
select concentrations that were not cytotoxic and significantly inhibited cell 102
proliferation. Cells were treated with test compounds for 46h before the 2h incubation 103
with MTT (final concentration 0.5 mg/ml). Hydrogen chloride 0.04M in isopropanol 104
was then added to dissolve the formazan crystals. The number of viable cells in each 105
well was estimated by the cell capacity to reduce MTT. The results were expressed as 106
percentage relative to the control (cells without any test compound). MTT reduction at 107
the beginning of incubation (t=0h) was subtracted from all the experimental conditions 108
used above, including the control.  Since the effects of the compounds were studied109
after 48h of incubation and cells grow significantly within this time period, the point at 110
the beginning of the incubation allows to distinguish between cell death and inhibition 111
of proliferation. MTT negative values indicate necrotic cell death due to cytotoxicity. 112
Values between 0% and 100% indicate inhibition of cell proliferation. 113
114
Assessment of proliferation by BrdU incorporation115
After 45h of treatment with test compounds at the chosen concentrations, cells 116
were incubated with bromodeoxyuridine 10µM (BrdU; Sigma-Aldrich) for another 3h. 117
7Both adherent and non-adherent cells were collected from each sample, fixed with 4% 118
paraformaldehyde for 15min at room temperature and attached into a polylysine treated 119
slide using a Shandon Cytospin (Thermo Fisher Scientific Inc, Waltham MA, USA).120
Cells were incubated with HCl 2M for 20min, washed in PBS containing 0.5% 121
Tween-20 and 0.05% BSA (TPBS-B) and then incubated with monoclonal mouse anti-122
BrdU antibody (DakoCytomation, Glostrup, Denmark) for 1h at room temperature. 123
After washing in TPBS-B, cells were incubated with anti-mouse IgG FITC conjugated 124
secondary antibody (Sigma-Aldrich) for 1h at room temperature, washed again and then 125
incubated with Hoechst for nuclei staining. The percentage of proliferating cells was 126
calculated as the ratio between BrdU positive cells and total cell number (nuclei staining 127
with Hoechst) from a count higher than 500 cells per slide under a fluorescence128
microscope. Results are presented as mean ± SEM of at least three independent 129
experiments.130
131
Assessment of apoptosis by TUNEL assay132
Cells treated with the tested compounds at chosen concentrations for 48h were 133
collected (both floating and attached cells) and fixed with 4% paraformaldehyde for 134
15min at room temperature and attached into a polylysine treated slide using a Shandon 135
Cytospin. Cells were washed in PBS and permeabilized with 0.1% Triton X-100 in 136
0.1% sodium citrate for 2min on ice. TUNEL (TdT mediated dUTP Nick End 137
Labelling) assay was performed using a kit from Roche (Mannheim, Germany), 138
following the manufacture’s instructions. Cells were incubated with Hoechst for nuclei 139
staining. The percentage of apoptotic cells was calculated from the ratio between 140
TUNEL positive cells and total number of cells (nuclei staining with Hoechst), from a 141
8count higher than 500 cells per slide under a fluorescence microscope. Results are 142
presented as mean ± SEM of at least three independent experiments.143
144
Protein extraction and western blotting145
After treatment with the chosen concentration of test compounds, cells were 146
washed with PBS and lysed for 15min at 4ºC with ice cold RIPA buffer (1% NP-40 in 147
150mM NaCl, 50mM Tris (pH 7.5), 2mM EDTA), supplemented with 20mM NaF, 148
1mM phenylmethylsulfonyl fluoride (PMSF), 20mM Na2V3O4 and protease inhibitor 149
cocktail (Roche, Mannheim, Germany). Protein concentration was quantified using a 150
Bio-Rad DC protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and BSA 151
used as a protein standard. Twenty micrograms of total protein from each cell lysate 152
were separated by SDS gel electrophoresis and then electroblotted to a Hybond-P 153
polyvinylidene difluoride membrane (GE Healthcare). Membranes were blocked in 154
TPBS (PBS with 0.05% Tween-20) containing 5% (w/v) non-fat dry milk or BSA 155
(bovine serum albumin), washed in TPBS and then incubated with primary antibody. 156
After washing, membranes were incubated with secondary antibody conjugated with 157
IgG horseradish peroxidase and immunoreactive bands were detected using the 158
Immobilon solutions (Millipore, Billerica, MA, USA) under a chemiluminescence 159
detection system, the Chemi Doc XRS (Bio-Rad Laboratories, Inc.). Band area intensity 160
was quantified using the Quantity One software from Bio-Rad. β-actin was used as 161
loading control. Results are presented as mean ± SEM of at least three independent 162
experiments. 163
164
Statistical analysis165
9One-way ANOVA followed by the Student-Newman-Keuls test was used to 166
perform statistical analysis, using GraphPad Prism 4.0 software (San Diego, CA, USA), 167
and P-values ≤ 0.05 were considered statistically significant. 168
169
Results 170
171
Effects of Q, L and UA on cell proliferation 172
In order to choose doses that do not cause significant toxicity (necrosis) and 173
have antiproliferative effects on the two human CRC derived cell lines, HCT15 and 174
CO115, a MTT assay was performed with different concentrations of the tested 175
compounds. The results showed that necrotic cell death (negative values in Figure 2) 176
occurred in HCT15 cells with L at 20µM and in CO115 with UA at 15µM. All the 177
tested compounds inhibited cell proliferation in a concentration-dependent manner in 178
both cell lines as shown by MTT assay (Figure 2). Both reference inhibitors, 179
wortmannin (W) and PD-98059 (PD), at the higher tested concentration did not induce 180
cell toxicity. Based on MTT results, three concentrations of Q, L and UA (2 in case of 181
CO115 cells) that inhibited cell proliferation without significant toxic effects, were 182
selected and used in the following BrdU and TUNEL assays. 183
For the BrdU incorporation assay, cells were treated with compounds for 48h. 184
As shown in Figure 3, a significant inhibition of proliferation indicated by lower levels 185
of BrdU incorporation was observed for Q, L and UA in both cell lines, in a dose 186
dependent manner. In HCT15 cells, the levels of BrdU incorporation decreased from 187
22.0% in the control to 5.2%, 3.4% and 9.8% in cells treated with Q 20µM, L 15µM188
and UA 4µM, respectively (Figure 3a). In CO115 cells, the percentage of cell 189
proliferation significantly decreased from 19.1% in the control to 3.8%, 11.1% and 190
10
10.2% in cells treated with Q 15µM, L 12µM and UA 10µM, respectively (Figure 3b). 191
The structurally-related flavonoids, Q and L, showed different responses in the two cell 192
lines: L was a stronger proliferation inhibitor in HCT15 than in CO115, whereas Q was 193
more effective in CO115 than in HCT15. The reference inhibitors, W, a PI3K inhibitor, 194
and PD, a phospho-ERK inhibitor, significantly inhibited cell proliferation in HCT15 195
and CO115 cells, respectively (Figure 3). 196
197
Effects of Q, L and UA on apoptosis  198
The ability of the test compounds to induce apoptosis was addressed by the 199
TUNEL assay. As shown in Figure 4, all compounds significantly induced apoptosis in 200
both HCT15 and CO115 cells. Apoptotic cells in HCT15 increased from 0.3% in the 201
control to 4.4%, 3.9% and 6.6% in cells treated with the higher concentrations of Q, L 202
and UA, respectively (Figure 4a). In CO115 cells, apoptotic cells increased from 1.9% 203
in the control to 36.2%, 15.1% and 12.4% in cells treated with the higher concentrations 204
of Q, L and UA, respectively (Figure 4b). Between the two flavonoids, Q seems to be a 205
more potent inducer of apoptosis in both cell lines compared to L. In addition, UA206
showed to be the most effective in HCT15, where it induced 20 times more apoptosis at 207
4µM when compared with control.208
209
Effects of Q, L and UA on ERK phosphorylation 210
Activation of MAPK/ERK pathway is representative of a large number of CRC 211
cases and the phosphorylation of ERK is an indicator of this activation. We observed 212
high levels of phospho-ERK in both cell lines (Figure 5). Incubations with L (15µM) 213
and Q (20µM) significantly decreased phospho-ERK protein level in HCT15 cells 214
(Figure 5a), but not in CO115 cells, while UA did not have any effect on either of the 215
11
cell lines (Figure 5a,b). A significant reduction of phospho-ERK by PD, a reference 216
inhibitor of MAPK/ERK pathway, was observed in both cell lines. Interestingly, L was 217
a stronger inhibitor of ERK in HCT15 cells than the reference inhibitor PD and than the 218
structure-related compound Q. 219
220
Effects of Q, L and UA on Akt phosphorylation 221
Because MAPK/ERK and PI3K/Akt pathways are both activated by RAS, we 222
also checked if the PI3K/Akt pathway was affected by the test compounds, measuring 223
phospho-Akt and phospho-PTEN expression levels. In HCT15 cells, there were no 224
detectable amounts of phospho-Akt, in incubations with and without serum (Figure 6a). 225
High expression levels of phospho-PTEN were detected in HCT15 cells but were not 226
altered by the test compounds (data not shown). In CO115 cells, phospho-Akt 227
expression was observed and significantly decreased by Q (15µM), L (12µM) and UA 228
(10µM), as shown in Figure 6b. Wortmannin, a reference PI3K inhibitor, also 229
significantly decreased Akt phosphorylation, contrarily to PD that did not alter230
phospho-Akt levels in CO115 cells. Phospho-PTEN and total PTEN expression were 231
not observed in CO115 cells, in medium with and without serum, in contrast with what 232
was observed with HCT15 cells (Figure 6c). The lack of phospho-Akt in HCT15 and 233
PTEN signal in CO115 cells was reproducible and checked in the presence of a positive 234
reactive sample (Figure 6a,c). These observations seem, therefore, also not to be the 235
result of protein degradation during protein extraction or sample preparation.236
237
Effects of Q, L and UA on KRAS and BRAF expression 238
To check if the effects of the tested compounds reflect direct effects on KRAS or 239
BRAF, expression of these proteins was also monitored by western blot. As shown in 240
12
figure 7, Q and L remarkably decreased the expression of KRAS but not BRAF in both 241
cell lines. UA significantly changed the expression of KRAS only in HCT15 cells, but 242
not as efficiently as the flavonoids. No significant changes were induced by UA in 243
BRAF expression. 244
245
Discussion246
The effects of quercetin (Q), luteolin (L) and ursolic acid (UA), natural 247
compounds common in diets rich in fruits and vegetables, were studied in two different 248
human colon carcinoma-derived cell lines representative of common CRC cases. We 249
observed that the three tested compounds, at concentrations that did not induce 250
significant cell toxicity (necrosis), inhibited proliferation and induced apoptosis in both 251
cell lines in a concentration-dependent manner. The purpose of the present study was to 252
identify in HCT15 and CO115 cells molecular targets for Q, L and UA related with 253
their antiproliferative and proapoptotic effects. HCT15 and CO115 have activating 254
mutations of KRAS and BRAF, respectively.   255
Q and L decreased the expression of phospho-ERK in the KRAS mutated256
HCT15 cell line but not in the BRAF mutated CO115 cell line. These results suggest 257
that the BRAF mutation in CO115 cells overrides any inhibitory effect of Q and L on 258
phospho-ERK, indicating that these flavonoids act on KRAS upstream of BRAF (Figure 259
8). This was further confirmed by a decrease in the expression of KRAS but not BRAF 260
induced by both flavonoids. Our findings corroborate recent reports where quercetin 261
treatment resulted in a reduction of Ras protein levels in colon cell lines expressing 262
oncogenic Ras [41, 42]. A recent study in skin epidermal cell line, showed a different 263
effect of quercetin, which in these cells inhibited both Raf and MEK activity [43]. In 264
addition, we observed in HCT15 cells that Q and L decreased phospho-ERK levels as265
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efficiently as PD-98059 (PD), a specific inhibitor of MEK downstream of RAF [44]. 266
Inhibition of proliferation and induction of apoptosis by Q and L in HCT15 cells does 267
however not seem to be due to phospho-ERK inhibition alone since PD inhibited 268
phospho-ERK but was without effect on cell proliferation and induction of apoptosis. 269
This finding is in agreement with other reports [10, 45], which showed that tumor cells 270
carrying KRAS mutation do not rely only on MAPK/ERK pathway to proliferate. Since 271
HCT15 cell proliferation was inhibited by wortmannin (W), a PI3K inhibitor, it seems 272
that inhibition of proliferation by Q and L treatment could be through inhibition of PI3K 273
dependent pathways. Contrarily to a previous report [46], we did not detect phospho-274
Akt in HCT15 cells, which could be explained by the high levels of phospho-PTEN 275
observed (Figure 8). It is known that other downstream targets of PI3K besides Akt also 276
contribute to cell proliferation and apoptosis, such as PKC, which is known to be 277
inhibited by Q and L [47-51]. PKC isozymes have been shown to be commonly 278
deregulated in colon cancer and other natural compounds, such as curcumin, have also 279
shown to inhibit PKC in CRC cells [17]. Thus, inhibition of proliferation in HCT15 280
cells by Q and L seems to be due to effects on KRAS, affecting not only the 281
MAPK/ERK pathway but also other alternative pathways, such as PI3K/PKC pathway.282
However, apoptosis induced by Q and L in HCT15 cells does not seem to be due to 283
inhibition of PI3K, since W did not induce apoptosis in this cell line. Other apoptotic 284
targets of these compounds should be considered. 285
Studies have shown that BRAF mutated cell lines rely more on MAPK/ERK 286
pathway for proliferation than KRAS mutated cell lines [10, 45]. However, our results 287
show that the dependence of CO115 cells on MAPK/ERK pathway for proliferation is 288
not exclusive, since all tested compounds inhibit proliferation without affecting 289
phospho-ERK levels. CO115 cells, besides harbouring a BRAF mutation, also present 290
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high PI3K activity [52]. In agreement with this, a high expression of phospho-Akt was 291
observed while PTEN was not detectable. Our results show a significant decrease in 292
phospho-Akt expression by Q, L and UA. These suggest an inhibition of PI3K activity,293
in addition to an inhibition of KRAS (Figure 8). Several studies have shown that 294
quercetin and analogs are potent inhibitors of PI3K activity [53, 54]. However, W 295
although inhibiting phospho-Akt, did not inhibit proliferation or induce apoptosis. The 296
effect of the natural compounds on PI3K may, therefore, only partially explain their 297
antiproliferative and proapoptotic activities in CO115 cells. The inhibition of phospho-298
Akt and phospho-ERK by Q and L has been reported in human hepatoma cell line 299
(HepG2) and brain tumors [55-57].300
Regarding UA, our results show that this compound does not affect phospho-301
ERK expression, being only effective in inhibiting phospho-Akt in CO115 cells. It 302
seems that UA does not affect significantly KRAS (although it decreased expression 303
levels in HCT15 cells) and has PI3K as one of its molecular targets. Interestingly, it was 304
the most efficient proliferation inhibitor and inducer of apoptosis in HCT15 cells, which 305
do not express phospho-Akt. Contrarily to the effects of the antioxidants Q and L, the 306
antitumor properties of UA through redox-sensitive pathways are most likely not the 307
result of its reactive oxygen species scavenging ability, since it was previously shown 308
that UA is inactive as free radical scavenger [32]. Interestingly, all tested compounds 309
showed to be more efficient than the reference compounds, PD and W, in inhibiting cell 310
proliferation and inducing apoptosis. Their wider range of molecular targets is therefore 311
advantageous in the control of tumor progression [26] and their importance of 312
modulating several signal transduction pathways associated with carcinogenesis is once 313
again reinforced.    314
15
In summary, the antiproliferative and proapoptotic effects of Q and L seem to 315
be, at least in part, due to effects on KRAS through regulation of both MAPK/ERK and 316
PI3K pathways. The BRAF mutation overrides the compounds` inhibition of KRAS on 317
the MAPK/ERK pathway but not on the PI3K pathway. UA seems to act on PI3K 318
where Q and L may also act, independently of KRAS mutation. The results of this study 319
suggest, therefore, the applicability of these phytochemicals in dietary strategies and as 320
possible adjuvants in CRC therapy both in KRAS and BRAF gene mutation profiles.321
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Figure legends
Fig. 1. Chemical structures of quercetin (Q), luteolin (L) and ursolic acid (UA). 
Fig. 2. Effect of different concentrations of quercetin (Q), luteolin (L) and ursolic acid 
(UA), for 48h on MTT reduction in HCT15 (a) and CO115 (b) cells. Wortmannin (W) 
and PD-98059 (PD) were used as reference inhibitors of PI3K/Akt and MAPK/ERK 
pathways, respectively. Values are mean ± SEM of at least 3 independent experiments. 
*P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001 when compared to control.
Fig. 3. Effect on cell proliferation of different concentrations of quercetin (Q), luteolin 
(L), ursolic acid (UA) and reference compounds, wortmannin (W) and PD-98059 (PD), 
for 48h in HCT15 (a) and CO115 (b) cells, using the BrdU incorporation assay. Values 
are mean ± SEM of at least 3 independent experiments. *P≤ 0.05, **P≤ 0.01 and ***P≤
0.001 when compared to control. 
Fig. 4. Effect on apoptosis of different concentrations of quercetin (Q), luteolin (L) and 
ursolic acid (UA) and reference compounds, wortmannin (W) and PD-98059 (PD), for 
48h in HCT15 (a) and CO115 (b) cells, using the TUNEL assay. Values are mean ± 
SEM of at least 3 independent experiments. *P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001 when 
compared to control. 
Fig. 5. Effects of quercetin (Q), luteolin (L) and ursolic acid (UA) for 24h on phospho-
ERK expression in HCT15 and CO115 cells, using western blot. β-Actin was used as 
loading control. (a) HCT15 cells were treated with L 15µM (L15), Q 20µM (Q20) and 
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UA 4 µM (UA4) in serum free medium. (b) CO115 cells were treated with 12µM L 
(L12), 15µM Q (Q15) and 10µM UA (UA10) in serum free medium. Wortmannin 1µM 
(W1) and PD-98059 50µM (PD50) were used as reference inhibitors of PI3K and MEK, 
respectively, in both cell lines. Values are mean ± SEM of at least 3 independent 
experiments. *P≤ 0.05 and **P≤ 0.01 when compared to control.
Fig. 6. Effects of quercetin (Q), luteolin (L) and ursolic acid (UA) for 24h on phospho-
Akt expression and phospho-PTEN levels in HCT15 and CO115 cells, using western 
blot. β-Actin was used as loading control. (a) HCT15 cells were cultured in medium 
without and containing 2% or 10% serum (FBS) and CO115 cells were cultured in 
serum free medium. (b) CO115 cells were treated with UA 10µM (UA10), Q 15µM 
(Q15) and L 12µM (L12) in serum free medium. Wortmannin 1µM (W1) and PD-98059 
50µM (PD50) were used as reference inhibitors of PI3K and MEK, respectively. (c) 
CO115 cells were cultured in medium without and containing 2% or 10% FBS and 
HCT15 cells were cultured in serum free medium. Values are mean ± SEM of at least 3 
independent experiments. ***P≤ 0.001 when compared to control.
Fig. 7. Effects of quercetin (Q), luteolin (L) and ursolic acid (UA) for 6h on KRAS and 
BRAF expression in HCT15 (a) and CO115 (b) cells, using western blot. β-Actin was 
used as loading control. Images and values are representative of three independent 
experiments.
Fig. 8. Schematic representation of possible targets of quercetin (Q), luteolin (L) and 
ursolic acid (UA) on MAPK/ERK and PI3K/Akt pathways in HCT15 and CO115 cell 
lines, which may lead to inhibition of cell proliferation and induction of apoptosis. 
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